Bladder Cancer Cell-Intrinsic PD-L1 Signals Affecting Virulence and Treatment Resistance
Abstract
Recent approvals of five distinct immunotherapy agents for BC have revolutionized the treatment of late-stage disease. Nevertheless, complete clinical responses to these immunotherapy agents are achieved in only a minority of patients and there are no unambiguous and reliable biomarkers to guide treatment selection. Thus, we need a greatly improved understanding of BC immunotherapy responses to help improve its efficacy and to develop useful treatment response biomarkers. We study novel BC-intrinsic PD-L1 signals that likely mediate important immunopathologic roles in BC, including mediating resistance to FDA-approved immunotherapies such as anti-PD-L1. These treatment response mechanisms and related biomarkers that we study here likely will also be useful in treatment applications in addition to immunotherapy and could apply to cancers in addition to BC.
Document Details
- Document Type
- Technical Report
- Publication Date
- Oct 01, 2021
- Accession Number
- AD1156778
Entities
People
- Tyler J Curiel
Organizations
- University of Texas at San Antonio